Delivery Order SPE2DB22D9239-SPE2DB25FDK68
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 22, 2025, for the supply of Jakafi 10 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of approximately $12.1K. The award represents a single delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA's SPE2DB program, a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 31, 2025, by the Defense Logistics Agency for the supply of Jakafi 10 mg tablets (60-count unit). This firm fixed-price delivery order, valued at $24,231.30, represents a single shipment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program. The contract includes no set-aside designation, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,115.65 by the Defense Logistics Agency on July 23, 2025, for the supply of Jakafi 10 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $48.6K on August 14, 2025, for the supply of Jakafi 5 mg tablets (60-count units) to support federal medical supply needs. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents execution under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, valued at $12,115.65, is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total contract value of $499,999,999 through...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $11,999.80 by the Defense Logistics Agency on September 11, 2025, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of September 12, 2025, represents a continuation of the company's substantial pharmaceutical supply relationship with the Department of Defense. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, valued at $36,115.27, represents a single issuance under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total value of $500...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $72,880.74 on August 11, 2025, for the supply of Jakafi 5 mg tablets (60-count units). The award was issued under a firm fixed-price contract with no set-aside designation and is set for ultimate completion by August 12, 2025. The contract is funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed at the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $12,115.65 for Jakafi 10 mg tablets (60-count units) by the Defense Logistics Agency's Medical Supply Chain on July 21, 2025, with an ultimate completion date of July 22, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the vendor's Park Ridge, Illinois facility. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 21, 2025, for the supply of Jakafi 20 mg tablets (60-count units). This firm fixed-price delivery order, valued at $12,089.78, represents a single line-item procurement without a set-aside designation, with an ultimate completion date of August 22, 2025. The award was issued under DMS...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDK68Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12.0K on July 22, 2025, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), the Department of Defense's combat support agency responsible for logistics and supply chain management. The award carries an ultimate completion date of July 23, 2025, and does not utilize a set-aside designation. The place of performance is located in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $500M vehicle that runs through November 2026 and enables the agency to procure a comprehensive range of pharmaceutical products to support military health facilities worldwide. Jakafi (ruxolitinib) is a prescription medication used to treat myelofibrosis and other blood disorders, reflecting the contractor's established role as a critical supplier of specialty pharmaceuticals and prescription medications to Department of Defense healthcare sites. The company has consistently demonstrated capability in delivering branded and generic prescription drugs, biologics, and medical consumables across various therapeutic categories to federal healthcare systems nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 7/22/25 |